Pfizer rolls out Retacrit, a biosim to Amgen and J&J anemia blockbusters, at a big discount

After experiencing slow uptake for its first biosim launch, Pfizer isn’t giving up on the budding field. On Wednesday, the drugmaker introduced its third biosim, and second in two months, launching anemia treatment Retacrit at a significant discount to Amgen’s Epogen and Johnson & Johnson’s Procrit. Pfizer started shipping Retacrit to wholesalers on Monday at… Read More »

CMS approves Michigan Medicaid drug value-based payment plan

Dive Brief: CMS Administrator Seema Verma announced Wednesday the agency has approved a Michigan plan allowing its state Medicaid program to work with drugmakers to allow value-based payment arrangements in an effort to “modernize payment policies.” The proposal is the second to receive a green light, following approval of a similar Oklahoma plan in June.  … Read More »